533 related articles for article (PubMed ID: 2422129)
61. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Itoh K; Pellis NR; Balch CM
Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
[TBL] [Abstract][Full Text] [Related]
62. Differences in murine gut-associated lymphoid tissues in generating broadly nonspecific cytotoxic cells in response to interferon alpha A/D and interleukin 2.
Chikkala NF; Gautam SC
Cell Immunol; 1991 Jul; 135(2):418-30. PubMed ID: 2036676
[TBL] [Abstract][Full Text] [Related]
63. Human recombinant interleukin-4 inhibits lymphokine-activated killer activity of sheep erythrocyte rosette-forming (E+) and -non-forming (E-) human lymphocytes.
Gerosa F; Tommasi M; Gerosa M; Tridente G
Int J Cancer; 1988 Dec; 42(6):902-5. PubMed ID: 3263954
[TBL] [Abstract][Full Text] [Related]
64. Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose.
Palmer PA; Scharenberg JG; von Blomberg BM; Stam AG; Meijer CJ; Roest GJ; Franks CR; Scheper RJ
Cancer Immunol Immunother; 1994 Jul; 39(1):34-40. PubMed ID: 8044824
[TBL] [Abstract][Full Text] [Related]
65. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production.
Amigorena S; Bonnerot C; Fridman WH; Teillaud JL
Eur J Immunol; 1990 Aug; 20(8):1781-7. PubMed ID: 1698633
[TBL] [Abstract][Full Text] [Related]
66. Analysis of the costimulatory role of IL-2 and IL-15 in initiating proliferation of resting (CD56dim) human NK cells.
Warren HS; Kinnear BF; Kastelein RL; Lanier LL
J Immunol; 1996 May; 156(9):3254-9. PubMed ID: 8617947
[TBL] [Abstract][Full Text] [Related]
67. In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).
Saijo N; Ozaki A; Nakano H; Sakurai M; Takahashi H; Sasaki Y; Hoshi A
J Cancer Res Clin Oncol; 1986; 111(3):182-6. PubMed ID: 3488319
[TBL] [Abstract][Full Text] [Related]
68. Restoring Natural Killer Cell Cytotoxicity After Hyperthermia Alone or Combined with Radiotherapy.
Hietanen T; Kapanen M; Kellokumpu-Lehtinen PL
Anticancer Res; 2016 Feb; 36(2):555-63. PubMed ID: 26851009
[TBL] [Abstract][Full Text] [Related]
69. Recombinant interleukin-2 inhibits growth of human tumor xenografts in congenitally athymic mice.
Bubeník J; Kieler J; Tromholt V; Indrová M; Lotzová E
Immunol Lett; 1987 Apr; 14(4):325-30. PubMed ID: 3495490
[TBL] [Abstract][Full Text] [Related]
70. Suppression by alpha-fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2.
Cohen BL; Orn A; Gronvik KO; Gidlund M; Wigzell H; Murgita RA
Scand J Immunol; 1986 Feb; 23(2):211-23. PubMed ID: 2419966
[TBL] [Abstract][Full Text] [Related]
71. Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.
Cordero OJ; Sarandeses CS; López JL; Nogueira M
Lymphokine Cytokine Res; 1992 Oct; 11(5):277-85. PubMed ID: 1467368
[TBL] [Abstract][Full Text] [Related]
72. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
McVicar DW; Merchant RE; Merchant LH; Young HF
Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
[TBL] [Abstract][Full Text] [Related]
73. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
74. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
75. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
76. Studies on the natural killer cell activity of human nonadherent mononuclear cells (nMNC) with tumor necrosis factor, interleukin-1, interferon-gamma and cisplatin.
Pai K; Sodhi A
Neoplasma; 1992; 39(6):363-7. PubMed ID: 1491726
[TBL] [Abstract][Full Text] [Related]
77. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
78. Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells.
Edwards BS; Merritt JA; Jelen PA; Borden EC
J Immunol; 1984 Jun; 132(6):2868-75. PubMed ID: 6202764
[TBL] [Abstract][Full Text] [Related]
79. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
Wright SC; Bonavida B
J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
[TBL] [Abstract][Full Text] [Related]
80. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
